Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 143

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 143
---
 of our common stock to be outstanding after this offering is based on 3,433,470 shares of common stock outstanding as of June 30, 2025, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering and excludes:

| • |     | 427,526 shares of common stock issuable upon the exercise of outstanding stock options under our 2023 Plan as of                 
 June 30, 2025, at a weighted-average exercise price of $41.84 per share (which does not take into account the Option Repricing); |

| • |     | 27,943 shares of common stock issuable upon the exercise of outstanding stock options under our 2018 Plan as of                  
 June 30, 2025, at a weighted-average exercise price of $66.40 per share (which does not take into account the Option Repricing); |

| • |     | 10,397 shares of common stock issuable upon the exercise of outstanding stock options under our 2017 Plan as of                  
 June 30, 2025, at a weighted-average exercise price of $49.81 per share (which does not take into account the Option Repricing); |

| • |     | 24,919 Class A common stock warrants to purchase 24,919 shares of our common stock, of which 24,919 Class A                                                                                                          
 common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Class A Warrants;” |

| • |     | 31,605 Class B common stock warrants to purchase 31,605 shares of our common stock, of which 31,605 Class B                                                                                                          
 common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Class B Warrants;” |

| • |     | 54,813 warrants held by Maxim Partners LLC to purchase 54,813 shares of our common stock of which 54,813 warrants                                                                            
 remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section